In recognition of the superior experience it has provided for patients over several years, Roswell Park Comprehensive Cancer Center has been designated by Press Ganey as a 2022 Human Experience (HX) Pinnacle of Excellence Award winner.

As it celebrates the achievements of some of the nation’s most respected and accomplished doctors, healthcare information resource Castle Connolly has recognized seven Roswell Park Comprehensive Cancer Center physician-oncologists as Exceptional Women in Medicine.

Underscoring Roswell Park Comprehensive Cancer Center’s ability to attract top clinical and research talent, Deputy Director Renier Brentjens, MD, PhD, has named physician-scientist Peter Maslak, MD, as Vice Chair of Clinical Affairs and Technical Director of the Clinical Flow Cytometry Laboratory.

Patients with esophageal cancer typically face a poor prognosis, largely because the disease is advanced at the time of diagnosis — and progress toward more-effective therapies has lagged. Now, armed with encouraging results from previous clinical trials, researchers at Roswell Park have launched two phase 2 clinical trials for esophageal cancer. Their goal: to determine whether a beta blocker called propranolol (brand name Inderal) can improve the efficacy of checkpoint inhibitors, a type of immunotherapy. Approved by the FDA in 1968, propranolol is commonly used to treat high blood pressure.